SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,000 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,000 shares of its common stock.

Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 Preliminary net product sales of $201 million for the full year 2022 SAN DIEGO, Jan.

SAN DIEGO , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube , Ph.D., president and chief executive officer, will present a corporate overview at the 41 st Annual J.P. Morgan Healthcare Conference , on Thursday, January 12, 2023 , at 11:15